NCT05517642View on ClinicalTrials.gov

IH Convidecia as Second Booster Dose Against Breakthrough Infections

PHASE3CompletedINTERVENTIONAL
Enrollment

540

Participants

Timeline

Start Date

September 20, 2022

Primary Completion Date

May 2, 2023

Study Completion Date

May 2, 2023

Conditions
COVID-19
Interventions
BIOLOGICAL

Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)

Subjects will be randomized to receive a second booster dose of IH Convidecia vaccine (treatment arm)

BIOLOGICAL

mRNA vaccine BNT162b2 (Pfizer)

Subjects will be randomized to receive a second booster dose of BNT162b2.

Trial Locations (1)

68000

Hospital Ampang, Ampang

Sponsors
All Listed Sponsors
lead

CanSino Biologics Inc.

INDUSTRY

NCT05517642 - IH Convidecia as Second Booster Dose Against Breakthrough Infections | Biotech Hunter | Biotech Hunter